Lung Metastases, Tumor Necrosis
Conditions
Brief summary
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.
Interventions
DRUGZoledronic Acid
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with osteosarcoma who were diagnosed with initial pathology and pathology were excluded from lung metastasis or other metastatic lesions by CT and total body emission-computed tomography, and patients with standard chemotherapy were evaluated.
Exclusion criteria
* Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine clearance \<70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. With diseases that still require hormone therapy, abnormal blood system, heart disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rate of lung metastasis | 3 year | Discovery the rate of neonatal lung metastases by high-resolution chest CT |
| rate of tumor recurrence | 3 year | Local recurrence rate of tumor or rate of distant metastasis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of tumor necrosis less than 90% | 3 year | the rate of patients that postoperative tumor necrosis rate was estimated to be lower than grade III（90%） |
Countries
China
Contacts
Primary ContactXiaobo Yan, Dr.
Outcome results
None listed